The potential of cellular homing behavior in tumor immunotherapy: from basic discoveries to clinical applications of immune, mesenchymal stem, and cancer cell homing DOI Creative Commons

Dongtao Li,

Yixuan Yang,

Guangda Zheng

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 12, 2024

The efficacy of immunotherapy, a pivotal approach in the arsenal cancer treatment strategies, is contingent on capacity effector cells to localize at tumor site. navigational these intricately linked homing behaviors specific cell types. Recent studies have focused leveraging immune and mesenchymal stem (MSCs) for targeted therapy incorporating properties into anti-tumor strategies. However, research development immunotherapy based remain their preliminary stages. Enhancing efficiency essential; therefore, understanding underlying mechanisms addressing resistance within microenvironment challenges associated with vivo therapeutic agent delivery are essential. This review firstly delineates discovery clinical translation three principal cell-homing behaviors. Secondly, we endeavor conduct an in-depth analysis existing therapy, aim identifying common applications, potential benefits, barriers, critical success factors cellular therapies. Finally, key therapies, provide overview outlook enormous harnessing cells’ self-homing treat tumors. Although behavior warrants further research, it remains highly competitive modality that can be combined classic anti-cancer In general, combining optimize effects also one future directions field transplantation.

Language: Английский

Advanced Delivery Systems for Gene Editing: A Comprehensive Review from the GenE-HumDi COST Action Working group DOI Creative Commons
Alessia Cavazza, Francisco J Molina-Estevez, Álvaro Plaza Reyes

et al.

Molecular Therapy — Nucleic Acids, Journal Year: 2025, Volume and Issue: 36(1), P. 102457 - 102457

Published: Jan. 18, 2025

Language: Английский

Citations

2
Basic Concepts and Indications of CAR T Cells DOI
J. Berg, Heinz Läubli, Nina Khanna

et al.

Hämostaseologie, Journal Year: 2025, Volume and Issue: 45(01), P. 014 - 023

Published: Feb. 1, 2025

Abstract Chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer immunotherapy, particularly for hematological malignancies. This personalized approach is based on genetically engineering cells derived from the patient to target antigens expressed—among others—on malignant cells. Nowadays they offer new hope where conventional therapies, such as chemotherapy and radiation, have often failed. Since first FDA approval in 2017, CAR rapidly expanded, proving highly effective against previously refractory diseases with otherwise a dismal outcome. Despite its promise, continues face significant challenges, including complex manufacturing, management of toxicities, resistance mechanisms that impact long-term efficacy, limited access well high costs, which continue shape ongoing research clinical applications. review aims provide an overview therapy, fundamental concepts, applications, current future directions

Language: Английский

Citations

1
TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges DOI Creative Commons

Elena A. Golikova,

Alina Alshevskaya, Saleh Alrhmoun

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 4, 2024

Language: Английский

Citations

6
Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers DOI
Hongli Gao,

Lianyue Qu,

Mu Li

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 297, P. 139829 - 139829

Published: Jan. 13, 2025

Language: Английский

Citations

0
Autologous Paracrine Prostasin–Matriptase Serine Protease Interaction in Lymphoid Cancer Cells DOI Creative Commons

Li-Mei Chen,

Karl X. Chai

Cells, Journal Year: 2025, Volume and Issue: 14(4), P. 247 - 247

Published: Feb. 10, 2025

The serine protease prostasin on the surface of exosomes released from epithelial cells can interact with ectopically over-expressed cell-surface matriptase in cancerous B to initiate prostasin–matriptase proteolytic activation cascade. Matriptase and ensuing self-activation result its removal cancer cells, reducing cell proliferation migration. In this study, we tested hypothesis that lymphoid could be removed by prostasin-initiated using genetically engineered autologous carrying prostasin. co-cultures prostasin-positive prostasin-negative vector-control was a dose-dependent manner, as determined flow cytometry. This paracrine phenotype requires active sites both proteases. silico analysis RNA-seq profiles indicated an imbalanced expression high low prostasin, their cognate inhibitors B-cell lymphoma patient specimens. impact exosomal cluster differentiation molecules activated human peripheral blood mononuclear investigated cytometry, revealing candidate mechanisms for prostasin’s role regulating cellular adaptive immunity. interaction exploited method targeting diseases such lymphoma.

Language: Английский

Citations

0
Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells DOI Open Access
Caroline Lonez,

Jennifer Bolsée,

Fanny Huberty

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1658 - 1658

Published: Feb. 15, 2025

With the success of chimeric antigen receptor (CAR) T-cell therapy in B-cell malignancies, efforts are being made to extend this other malignancies and broader patient populations. However, limitations associated with time-consuming highly personalized manufacturing autologous CAR T-cells remain. Allogeneic approaches may overcome these challenges but require further engineering reduce their alloreactivity. As a means prevent graft-versus-host disease (GvHD) allogeneic T-cells, we have selected micro RNA (miRNA)-based short hairpin (shRNA) targeting CD3ζ which efficiently downregulates expression (TCR) below detection level. We generated anti-B-cell maturation (CYAD-211) that co-express an anti-CD3ζ miRNA-based shRNA within construct inhibited TCR-mediated signaling vitro GvHD vivo. CYAD-211 was subsequently evaluated Phase-I clinical trial (NCT04613557), patients relapsed or refractory multiple myeloma. No signs were observed despite evidence engraftment, demonstrating efficient downregulation TCR. Our data provide proof concept non-gene-edited technology can generate fully functional without any GvHD. is needed improve persistence long-term activity.

Language: Английский

Citations

0
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment DOI Creative Commons
Xuejia Kang, Nur Mita, Lang Zhou

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(9), P. 1228 - 1228

Published: Sept. 20, 2024

Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for hematological cancers, yet it faces significant hurdles, particularly regarding its efficacy in solid tumors and concerning associated adverse effects. This review provides comprehensive analysis of the advancements ongoing challenges CAR-T therapy. We highlight transformative potential nanotechnology enhancing by improving targeting precision, modulating immune-suppressive tumor microenvironment, overcoming physical barriers. Nanotechnology facilitates efficient CAR gene delivery into cells, boosting transfection efficiency potentially reducing costs. Moreover, offers innovative solutions to mitigate cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity (ICANS). Cutting-edge platforms real-time monitoring activity are also discussed. By integrating these advancements, we aim provide valuable insights pave way next generation therapies overcome current limitations enhance therapeutic outcomes.

Language: Английский

Citations

2
Egg Cooling After Oviposition Extends the Permissive Period for Microinjection-Mediated Genome Modification in Bombyx mori DOI Open Access
Keiro Uchino, Ryusei Waizumi, Megumi Sumitani

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12642 - 12642

Published: Nov. 25, 2024

In general, transgenesis efficiency is largely dependent on the developmental status of eggs for microinjection. We investigated whether relationship between and cooling in silkworms,

Language: Английский

Citations

0
The potential of cellular homing behavior in tumor immunotherapy: from basic discoveries to clinical applications of immune, mesenchymal stem, and cancer cell homing DOI Creative Commons

Dongtao Li,

Yixuan Yang,

Guangda Zheng

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 12, 2024

The efficacy of immunotherapy, a pivotal approach in the arsenal cancer treatment strategies, is contingent on capacity effector cells to localize at tumor site. navigational these intricately linked homing behaviors specific cell types. Recent studies have focused leveraging immune and mesenchymal stem (MSCs) for targeted therapy incorporating properties into anti-tumor strategies. However, research development immunotherapy based remain their preliminary stages. Enhancing efficiency essential; therefore, understanding underlying mechanisms addressing resistance within microenvironment challenges associated with vivo therapeutic agent delivery are essential. This review firstly delineates discovery clinical translation three principal cell-homing behaviors. Secondly, we endeavor conduct an in-depth analysis existing therapy, aim identifying common applications, potential benefits, barriers, critical success factors cellular therapies. Finally, key therapies, provide overview outlook enormous harnessing cells’ self-homing treat tumors. Although behavior warrants further research, it remains highly competitive modality that can be combined classic anti-cancer In general, combining optimize effects also one future directions field transplantation.

Language: Английский

Citations

0